Dimerix Limited (ASX:DXB) Secures Major Licensing Deal in Japan and FDA Endorsement for DMX-200
Dimerix Limited (ASX:DXB) secures a ¥10.5 billion licensing deal in Japan and receives FDA endorsement for its DMX-200 therapy.
Category: Healthcare
BPH Global Limited (ASX:BP8) Releases Quarterly Activities Report and Secures Funding
BPH Global Limited (ASX:BP8) releases Q1 2025 report, secures $609K funding, and advances Indonesian seaweed projects.
ImpediMed Limited (ASX:IPD) Announces Q3 Revenue and ARR Growth
ImpediMed Limited (ASX:IPD) reports record Q3 revenue and ARR growth, along with key operational and management developments.
Mesoblast Limited (ASX:MSB) Announces Q3 2025 Highlights
Mesoblast Limited (ASX:MSB) reports Q1 2025 milestones, including the US launch of Ryoncil® and strong financial performance.
EMVision Medical Devices Limited (ASX:EMV) Launches Clinical Trial for emu™ Device
EMVision Medical Devices Limited (ASX:EMV) has commenced pivotal clinical trials for its emu™ brain scanner and announced successful device testing and robust cash reserves.
Starpharma (ASX:SPL) Announces Q3 FY25 Activities Report
Starpharma (ASX:SPL) announces Q3 FY25 report with advancements in partnerships, product launches, and financial performance.
MedAdvisor Limited (ASX:MDR) Releases 3Q FY25 Financial Update
MedAdvisor Limited (ASX:MDR) reports a significant decrease in 3Q FY25 revenue, announces cost-cutting measures and strategic initiatives.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) Announces Phase 3 Trial Launch and Financial Update
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
InteliCare Holdings Ltd (ASX:ICR) Partners with mecwacare for AI Platform Trial at Trescowthick Centre
InteliCare Holdings Ltd (ASX:ICR) partners with mecwacare to trial its AI-driven platform at Trescowthick Centre, enhancing aged care services in Victoria.
4DMedical Limited (ASX:4DX) Reports 103% Revenue Growth and Strategic Milestones
4DMedical Limited (ASX:4DX) achieves 103% YTD revenue growth and secures key strategic partnerships in Q3 FY2025.